The global kidney function tests market size was valued at USD 845.9 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 6.50% from 2023 to 2030. Various factors, such as increasing investments by market players, rising R&D activities, high prevalence of kidney diseases, rising government initiatives, and technological innovations are expected to significantly drive market growth. For instance, in March 2022, Nova Biomedical launched a novel tool to advance kidney care through early detection of the disease and renal function screening in POCT settings outside the hospital. The company’s technology has been proven in clinical studies in various non-hospital settings, including community health centers, pharmacies, imaging centers, physician offices, clinics, and home testing by individuals.
During the COVID-19 pandemic, there has been an increase in the number of renal injury cases. Early studies discovered that patients with renal disease are at a higher risk of severe complications and worse outcomes if they catch COVID-19 infection. Ongoing clinical researches pertaining to the long-term effects of COVID-19 indicate more evidence of a long-lasting effect on renal health. However, the COVID-19 pandemic has negatively affected the healthcare services for kidney disease patients. Social distancing and lockdown were a global mandate, leading to the temporary closure of other medical services. The diagnosis of several kidney diseases was deferred due to the suspension of non-emergency visits and tests, adhering to the COVID-19 measures in the peak phases.
The growing prevalence of acute kidney injury (AKI) and associated chronic kidney disease (CKD) is projected to drive the kidney function tests market during the forecast years. CKD means persistent renal function and structural deformities that have been present for a minimum of 3 months. Lifestyle diseases and kidney injuries are significant risk factors for CKD. CKD is a global health challenge. It is the foremost cause of illness and death globally. According to WHO, in the past 9 years, the incidence of kidney disease has increased to become one of the top 10 prominent causes of death globally. According to National Kidney Foundation, Inc., an estimated 37 million people in the U.S., i.e., more than one in seven adults, are living with some form of renal disease.
Furthermore, the increased adoption of digital urinalysis indicates the growing demand for home diagnostics, which is driving market growth. Recognizing the trend, Healthy.io, a start-up in digital health headquartered in Israel, developed an FDA-cleared at-home smartphone urinalysis test to help people seeking kidney tests for proteins. Early detection helps avoid complications from kidney diseases. The company’s urinalysis test, Dip.io, uses disposable cups and strips in combination with a smartphone camera to interpret & read results. In addition, the test has been evaluated with Geisinger Health in conjunction with NKF, reaching a 71% adherence rate with hypertension patients who have never been tested earlier. Moreover, the start-up is driven by rapidly evolving smartphone technology.
Moreover, rising R&D initiatives for the development of novel products are expected to significantly boost the kidney function tests market growth during the forecast period. For instance, KidneyX is a public-private partnership between the U.S. Department of Health and Human Services and the American Society of Nephrology to fast-track innovation in the treatment, diagnosis, and prevention of renal diseases. It seeks to improve the lives of the 850 million people globally, who have been recently affected by kidney diseases, by fast-tracking the development of devices, drugs, biologics, and other therapies in renal care. In addition, the Canadian kidney research organization received USD 11.8 million in investment to support its work through 2027. The Can-SOLVE Chronic Kidney Disease Network is the largest-ever kidney research initiative in Canada. It is a partnership of scientists, healthcare professionals, and patients working on ways to help the almost 4 million Canadians affected by CKD.
Additionally, technological advancements associated with kidney function tests are likely to offer lucrative opportunities during the projected timeframe. For instance, in August 2022, Bloom Diagnostics developed a smart system that detects a broad range of medical disorders. The Bloom Kidney Test is the latest addition to its portfolio. It is used for the quantitative measurement of cystatin C in the bloodstream to evaluate GFR, which specifies if the kidneys are working in good condition. The test provides three different classifications—mildly decreased function, indicating normal function, and decreased function. Hence, such developments are anticipated to boost market growth.
In 2022, the clearance tests segment accounted for the major market share of 28.05% and is expected to hold its dominance during the forecast period. Clearance tests are the gold standard for monitoring and measuring glomerular filtration rate. These products include creatinine and inulin tests, which are important additions to traditional diagnostic tests to obtain precise results. Moreover, these tests ensure that there is minimal variation in performance owing to their optimum sensitivity and precision. The low cost and easy availability of these products in the market lead to their increased adoption.
The urine tests segment is projected to witness significant a CAGR of 7.61% during the forecast years. One of the most frequently used procedures for assessing renal function is urea quantification. Urine, plasma, and serum urea analyses are crucial clinical tests for detecting renal illness and dysfunction. For the diagnosis of pre-renal, renal, and post-renal uremia, urine tests are frequently performed in conjunction with creatinine determination tests. Furthermore, growing investments in the renal function testing industry are also anticipated to support market expansion. For instance, in January 2020, Sweden-based Elypta AB raised seed financing of USD 7.0 million to provide the first urine test for renal cancer.
The hospital’s segment held 40.90% of the market share in 2022, owing to the surge in hospitalization, doctors require diagnostic interpretation for further treatment. Usually, diagnostic centers function in association with hospitals; hence, hospitals have their diagnostic setup. Moreover, the ongoing development of healthcare infrastructure is likely to enhance existing hospital facilities, expanding their services and offerings. Thus, this expansion may boost the demand for products such as kidney function tests, thereby driving the market. In addition, favorable reimbursement scenarios and an increase in the number of initiatives being undertaken by healthcare organizations globally to promote the use of advanced diagnostic tests are also likely to propel segment growth.
The diagnostic laboratories segment is anticipated to be the fastest-growing segment with a CAGR of 7.95%. Owing to the increase in awareness about CKD, the rise in the demand for affordable services, and rapid technological advancements are some of the key factors expected to boost segment growth. A growing number of initiatives undertaken by governments to provide various facilities, such as reimbursement for diagnostic tests, is another major factor likely to drive the market.
North America dominated the overall market in terms of revenue in 2022. This dominance is due to well-established healthcare infrastructure, high awareness of CKD, and favorable reimbursement policies and government initiatives. Moreover, the leading manufacturers in the region are focused on developing innovative products. For instance, in November 2021, Abbott HealthTab, Inc. signed a non-assignable, pilot supplier distribution agreement with Abbott for i-STAT Alinity, a handheld blood chemistry analyzer. The agreement permits HealthTab to distribute Abbott’s POC i-STAT Alinity and its related tests for creatinine in Canadian drug stores to help patients gain vital information about their kidney functions.
Asia Pacific is anticipated to witness a significant CAGR of 8.34% during the assessment period owing to the rising prevalence of kidney disease in the region. For instance, in 2020, according to the Australian Institute of Health and Welfare, around 17,700 population were mortal due to CKD. Around 11% of deaths in Australia are caused due to CKD. In addition, countries such as China and Japan have introduced several awareness programs about CKD, which is likely to promote the kidney function tests market growth in the forecast period.
Key players in this market are implementing various strategies including new product launches, geographical expansion, partnerships, and collaborations to expand their market presence. For instance, in March 2022, Nova Biomedical launched a novel tool to advance renal care through kidney function screening and detection of kidney disease in POC settings outside the hospital. In addition, in November 2021, HealthTab, Inc. signed a non-assignable and pilot supplier distribution agreement with Abbott for i-STAT Alinity, the handheld blood chemistry analyzer. This agreement permits HealthTab to distribute Abbott’s POC i-STAT Alinity and its related tests for creatinine in Canadian drugstores to help patients with vital information about their renal function. Some of the key players in the global kidney function tests market include:
F. Hoffmann-La Roche Ltd.
Randox Laboratories Ltd
ACON Laboratories, Inc.
Nova Biomedical Corporation
Laboratory Corporation of America Holdings
Market size value in 2023
USD 895.6 million
Revenue forecast in 2030
USD 1.39 billion
CAGR of 6.50% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, end-use, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; Russia; Japan; China; India; South Korea; Australia; Singapore; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled
Abbott; Danaher; F. Hoffmann-La Roche Ltd.; Sysmex Corporation; Siemens Healthineers; Randox Laboratories Ltd; Quest Diagnostics; ACON Laboratories, Inc.; Nova Biomedical Corporation; Laboratory Corporation of America Holdings
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the kidney function tests market report based on product, end-use, and region.
Product Outlook (Revenue, USD Million, 2018 - 2030)
Dilution And Concentration Tests
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Research Laboratories And Institutes
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global kidney function tests market size was estimated at USD 845.9 million in 2022 and is expected to reach USD 895.6 in 2023.
b. The global kidney function tests market is expected to grow at a compound annual growth rate of 6.50% from 2022 to 2030 to reach USD 1.39 billion by 2030.
b. The clearance tests segment dominated the market for kidney function tests and accounted for the largest revenue share of 28.05% in 2022.
b. Some key players operating in the kidney function tests market include Abbott, Danaher, F. Hoffmann-La Roche Ltd., Sysmex Corporation, Siemens Healthcare GmbH, Randox Laboratories, Quest Diagnostics, and Laboratory Corporation of America Holdings.
b. Key factors that are driving the kidney function tests market growth include the growing prevalence of chronic kidney diseases and technological advancements in renal function tests.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."